Overview

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Status:
Completed
Trial end date:
2020-04-07
Target enrollment:
Participant gender:
Summary
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
Phase:
Phase 2
Details
Lead Sponsor:
Tenax Therapeutics, Inc.
Treatments:
Pharmaceutical Solutions
Simendan